Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun;10(3):705-716.
doi: 10.1002/epi4.70007. Epub 2025 Apr 30.

Antiseizure medication choice in diffuse glioma: A single-center population-based experience

Leena Ollila  1 , Reina Roivainen  1
Affiliations

Antiseizure medication choice in diffuse glioma: A single-center population-based experience

Leena Ollila et al. Epilepsia Open. 2025 Jun.

Abstract

Objective: Several antiseizure medications (ASMs) can be considered as first-line treatment for glioma-associated epilepsy (GAE). We aimed to find out, if there are subgroups of glioma patients which may benefit from different first-line ASMs.

Methods: All diffuse glioma (grade 2-4) patients, who were in contact with Helsinki University Hospital Neurology or Oncology Departments during 2013-2015, were recognized from medical records. Follow-up data was retrospectively collected of all GAE patients living in Helsinki for 5 years from diagnosis of glioma, or until death.

Results: A total of 121 patients with GAE fulfilling inclusion criteria were identified. Forty-nine (40.5%) had grade 2 glioma, 18 (14.9%) had grade 3 glioma, and 54 (44.6%) had grade 4 glioma. The most common first ASM was oxcarbazepine (39.2%), followed by levetiracetam (22.5%), carbamazepine (19.3%), phenytoin (10.8%) and valproic acid (8.3%). The first ASM was retained in use in 70 (57.9%) patients until the end of follow-up. Among patients with low-grade glioma, oxcarbazepine was favored, whereas grade 4 glioma patients more often received levetiracetam as first ASM. At the end of follow-up, the retention rate of levetiracetam as first ASM was higher than retention rate of other ASMs in grade 4 glioma patients (p 0.002). Patients who initiated valproic acid as first ASM underwent more ASM changes than patients who initiated other first-line ASM (p 0.005).

Significance: Levetiracetam seems to be a favorable first-line treatment for GAE, especially for patients with grade 4 glioma. For grade 2-3 glioma patients, oxcarbazepine may be a reasonable option.

Plain language summary: Grade 2-4 gliomas are central nervous system tumors originating from glial cells, and epilepsy is common in glioma patients. We found that levetiracetam was favored as first antiseizure medication for patients with malignant, grade 4, glioma. For patients with slower-growing tumors, grade 2-3 gliomas, oxcarbazepine may be a reasonable choice for first antiseizure medication. The findings highlight the need for individual assessment in the use of antiseizure medications in glioma patients.

Keywords: antiseizure medication retention; brain tumor; epilepsy; seizures.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Reasons for changes of ASMs. ASMs, CBZ, carbamazepine; CLB, clobazam; CLN, clonazepam; LCM, lacosamide; LEV, levetiracetam; LTG, lamotrigine; OXC, oxcarbazepine; PGB, pregabalin; PHT, phenytoin; TPM, topiramate; VPA, valproic acid.
See this image and copyright information in PMC

References

    1. van Breemen MS, Wilms EB, Vecht CJ. Epilepsy in patients with brain tumours: epidemiology, mechanisms, and management. Lancet Neurol. 2007;6(5):421–430. 10.1016/S1474-4422(07)70103-5 - DOI - PubMed
    1. Ollila L, Roivainen R. Glioma features and seizure control during long‐term follow‐up. Epilepsy Behav Rep. 2023;21:100586. 10.1016/j.ebr.2023.100586 - DOI - PMC - PubMed
    1. Klein M, Engelberts NHJ, Van Der Ploeg HM, Kasteleijn‐Nolst Trenité DG, Aaronson NK, Taphoorn MJ, et al. Epilepsy in low‐grade gliomas: the impact on cognitive function and quality of life. Ann Neurol. 2003;54(4):514–520. 10.1002/ana.10712 - DOI - PubMed
    1. Blond BN, Detyniecki K, Hirsch LJ. Assessment of treatment side effects and quality of life in people with epilepsy. Neurol Clin. 2016;34(2):395–410. 10.1016/j.ncl.2015.11.002 - DOI - PubMed
    1. Koekkoek JAF, Dirven L, Heimans JJ, Postma TJ, Vos MJ, Reijneveld JC, et al. Seizure reduction in a low‐grade glioma: more than a beneficial side effect of temozolomide. J Neurol Neurosurg Psychiatry. 2015;86(4):366–373. 10.1136/jnnp‐2014‐308136 - DOI - PubMed

MeSH terms